Clinicopathological features and prognostic factors of rare primary bone
marrow diffuse large B cell lymphoma
Background: Primary bone marrow diffuse large B-cell lymphoma
(PBM-DLBCL) is a rare hematological malignancy with a poor prognosis.
The lack of a clear definition and unified diagnostic criteria for this
disease in the WHO classification poses challenges for its diagnosis and
management. Patients and Methods: To gain insights into the
clinicopathological characteristics of PBM-DLBCL and explore prognostic
factors, we conducted a study using data from our center and published
literature spanning from 2001 to 2022. A total of 70 patients were
included in our analysis. Results: Univariate analysis revealed that
patients presenting with B symptoms and higher IPI scores tended to have
a poorer prognosis, although statistical significance was not achieved
(P>0.05). However, patients who attained a complete
response (CR) after initial therapy exhibited better outcomes (P=0.007).
Intensive treatment regimens demonstrated potential benefits over
general treatment approaches. Additionally, our investigation suggested
that rituximab-based chemotherapy was associated with improved prognoses
compared to other general regimens. Conclusion: PBM-DLBCL is an
aggressive disease with distinct clinical, pathological, and imaging
features. It is crucial to understand the clinical characteristics of
PBM-DLBCL, identify clinical risks in a timely manner, and determine
appropriate treatment regimens.